低剂量大环内酯类治疗慢性鼻窦炎成功的影响因素:系统评价与荟萃分析
该系统评价与荟萃分析纳入10项随机对照试验共608例患者,评估低剂量大环内酯类治疗慢性鼻窦炎的预后因素。低剂量大环内酯类与安慰剂在SNOT改善上无差异(SMD=-0.23,95%CI:-0.69至0.24);亚组分析显示无鼻息肉患者及接受半剂量者效果更优,疗程24周优于8周和12周。
要点
- 低剂量大环内酯类与安慰剂在SNOT改善上无显著差异(SMD=-0.23,95%CI:-0.69至0.24)。
- 无鼻息肉患者亚组SMD=-0.64(95%CI:-1.01至-0.27),优于有鼻息肉患者。
- 半剂量亚组SMD=-0.64(95%CI:-1.01至-0.27),优于极低剂量组。
核心结论
- 低剂量大环内酯类在无鼻息肉慢性鼻窦炎患者中提供有利结局。
- 应给予半剂量大环内酯类,疗程24周。
研究设计与样本
- 系统评价与荟萃分析,纳入研究低剂量大环内酯类治疗慢性鼻窦炎的随机对照试验。
- 共纳入10项研究,608例患者。
主要发现
- 低剂量大环内酯类与安慰剂在SNOT改善上无差异(SMD=-0.23,95%CI:-0.69至0.24)。
- 无鼻息肉患者亚组SMD=-0.64(95%CI:-1.01至-0.27),优于有鼻息肉患者。
- 半剂量亚组SMD=-0.64(95%CI:-1.01至-0.27),优于极低剂量组。
- 低剂量大环内酯类联合标准治疗与标准治疗相比SNOT改善无差异(SMD=-0.52,95%CI:-1.57至0.53)。
- 疗程24周亚组SMD=-1.68(95%CI:-2.40至-0.95),优于8周和12周;14元环与15元环大环内酯类之间无差异;同期ESS评估结果不一;血清IgE水平未能评估。
关键数值与推荐
- 主要结局为SNOT(鼻窦炎结局测试)。
- 评估的预后因素包括:慢性鼻窦炎亚型、血清IgE水平、大环内酯类内酯环元数、同期ESS、低剂量大环内酯类的剂量和疗程。
临床怎么用
- 作者认为,低剂量大环内酯类在无鼻息肉慢性鼻窦炎患者中提供有利结局。
- 作者建议,应给予半剂量大环内酯类,疗程24周。
局限性
- 血清IgE水平未能评估。
- 同期ESS评估结果不一。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To assess the prognostic factors that predict favorable outcomes of low-dose macrolides (LDMs) in treating chronic rhinosinusitis (CRS). METHODS: Randomized controlled trials studying the effects of LDMs in treating CRS were included. Data were pooled for meta-analysis. Primary outcome was Sino-Nasal Outcome Test (SNOT). Six prognostic factors: CRS subtypes, serum immunoglobulin (Ig)E level, membered lactone ring of macrolides, concurrent endoscopic sinus surgery (ESS), and dosage and duration of the LDMs were assessed by subgroup analyses. RESULTS: Ten studies (608 patients) met the inclusion criteria. LDMs and placebo were not different in SNOT improvement (standardized mean difference [SMD] = -0.23, 95% confidence interval [CI]: -0.69 to 0.24). Subgroup analyses showed that the effects favored LDMs in the patients with CRS without polyps (SMD = -0.64, 95% CI: -1.01 to -0.27) compared to CRS with polyps, and the patients receiving a half dose (SMD = -0.64, 95% CI: -1.01 to -0.27) compared to a very low dose. There was no difference in SNOT improvement between LDMs plus standard treatment compared to standard treatment (SMD = -0.52, 95% CI: -1.57 to 0.53). Subgroup analyses showed that the effects favored LDMs in the patients receiving LDMs for a duration of 24 weeks (SMD = -1.68, 95% CI: -2.40 to -0.95) compared to 8 and 12 weeks. There was no difference between the 14-membered and 15-membered ring LDMs. Assessment of concurrent ESS found mixed results. Serum IgE level could not be assessed. CONCLUSIONS: LDMs provided favorable outcomes in patients with CRS without polyps. A half dose of macrolides should be given for a duration of 24 weeks. LEVEL OF EVIDENCE: 1a Laryngoscope, 129:1510-1519, 2019.
引用
- Seresirikachorn K, Suwanparin N, Srisunthornphanich C, et al. Factors of success of low-dose macrolides in chronic sinusitis: Systematic review and meta-analysis. Laryngoscope. 2019. PMID: 30746710. doi:10.1002/lary.27865
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。